UBS Group’s Translational Development Acquisition Corp TDAC Stock Holding History
Bought
Maintained
Sold
Other funds holding TDAC
UBS Group's TDAC Position: Q3 2026 in Review
UBS Group opened a new position in Translational Development Acquisition Corp (TDAC) in Q3 2026: 2,237 shares worth $24.2K. The stake represents ﹤0.01% of the portfolio and ranks #8324 among its holdings. This is a return to the name: UBS Group previously reported a position in TDAC as recently as Q1 2026.
UBS Group first reported a position in TDAC in Q1 2025 and has held it in 6 quarters since. The position peaked at $352K in Q3 2025. 37 funds tracked by Wall St. Rank hold TDAC as of Q3 2026.
- UBS Group held 2,237 shares of Translational Development Acquisition Corp worth $24.2K as of Q3 2026.
- Translational Development Acquisition Corp was a new UBS Group position in Q3 2026.
- Translational Development Acquisition Corp made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #8324 holding.
- UBS Group first reported a position in Translational Development Acquisition Corp in Q1 2025 and has held it in 6 quarters since.
- UBS Group's Translational Development Acquisition Corp position peaked at $352K in Q3 2025.
- 37 funds tracked by Wall St. Rank held Translational Development Acquisition Corp as of Q3 2026.
Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.